Intellia Therapeutics has been granted a patent for a genome editing system focused on immunooncology. The composition includes gRNA and Cas9 molecules targeting specific sequences within the TET2 gene, offering potential advancements in cancer treatment. GlobalData’s report on Intellia Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Intellia Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to GlobalData’s company profile on Intellia Therapeutics, CRISPR genome editing was a key innovation area identified from patents. Intellia Therapeutics's grant share as of February 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.

Genome editing system for immunooncology

Source: United States Patent and Trademark Office (USPTO). Credit: Intellia Therapeutics Inc

A recently granted patent (Publication Number: US11851659B2) discloses a composition comprising a gRNA molecule or a nucleic acid sequence encoding the gRNA molecule, along with a Cas9 molecule or a nucleic acid sequence encoding the Cas9 molecule. The gRNA molecule consists of a tracr and crRNA, with the crRNA containing a targeting domain complementary to specific sequences within the TET2 gene. The composition also includes various modifications and extensions to the gRNA molecule, allowing for precise targeting and alteration of the TET2 gene in cells. Additionally, the composition can be formulated for use in electroporation and can be present in a ribonuclear protein complex (RNP) for efficient delivery and function.

Furthermore, the patent claims cover methods of altering target sequences in cells, reducing or eliminating the expression of TET2 isoforms, and engineering cells to express chimeric antigen receptors (CARs) using the disclosed composition. These methods involve introducing the composition into cells, along with template nucleic acids encoding CARs, in various vectors such as AAV vectors. The methods also include introducing additional CRISPR systems targeting specific genes related to immune response and cell function. Overall, the patent provides a comprehensive approach to genome editing and cell engineering, offering potential applications in research, therapeutics, and biotechnology.

To know more about GlobalData’s detailed insights on Intellia Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies